DOCSLIB.ORG

Differential Urinary Proteins Between AHSP and Healthy Children Using the DDA Method

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differential Urinary Proteins Between AHSP and Healthy Children Using the DDA Method Differential urinary proteins between AHSP and healthy children using the DDA method Ratio of Uniprot ID Protein description Gene name Average of AHSP Average of HC AHSP/HC or P value HC/AHSP Tumor necrosis factor receptor superfamily member 13C (B-cell- Q96RJ3 activating factor receptor) (BAFF receptor) (BAFF-R) (BLyS receptor 3) TNFRSF13C 0.000 1.0 Infinity 0.004 (CD antigen CD268) Soluble scavenger receptor cysteine-rich domain-containing protein A1L4H1 SSC5D 0.000 0.8 Infinity 0.008 SSC5D (Soluble scavenger protein with 5 SRCR domains) (SSc5D) Xaa-Pro dipeptidase (X-Pro dipeptidase) (EC 3.4.13.9) P12955 PEPD 1.333 0.0 Infinity 0.012 (Imidodipeptidase) (Peptidase D) (Proline dipeptidase) (Prolidase) Dihydropteridine reductase (EC 1.5.1.34) (HDHPR) (Quinoid P09417 dihydropteridine reductase) (Short chain dehydrogenase/reductase family QDPR 2.133 0.0 Infinity 0.014 33C member 1) Cytosolic 10-formyltetrahydrofolate dehydrogenase (10-FTHFDH) O75891 ALDH1L1 1.800 0.0 Infinity 0.018 (FDH) (EC 1.5.1.6) (Aldehyde dehydrogenase family 1 member L1) V-type proton ATPase subunit B, brain isoform (V-ATPase subunit B 2) P21281 (Endomembrane proton pump 58 kDa subunit) (HO57) (Vacuolar proton ATP6V1B2 1.533 0.0 Infinity 0.028 pump subunit B 2) Bifunctional epoxide hydrolase 2 [Includes: Cytosolic epoxide hydrolase P34913 2 (CEH) (EC 3.3.2.10) (Epoxide hydratase) (Soluble epoxide hydrolase) EPHX2 0.933 0.0 Infinity 0.032 (SEH); Lipid-phosphate phosphatase (EC 3.1.3.76)] Sodium/potassium-transporting ATPase subunit beta-1 P05026 ATP1B1 0.933 0.0 Infinity 0.032 (Sodium/potassium-dependent ATPase subunit beta-1) P25774 Cathepsin S (EC 3.4.22.27) CTSS 2.600 0.0 Infinity 0.033 P07741 Adenine phosphoribosyltransferase (APRT) (EC 2.4.2.7) APRT 0.867 0.0 Infinity 0.035 Pterin-4-alpha-carbinolamine dehydratase (PHS) (EC 4.2.1.96) (4-alpha- hydroxy-tetrahydropterin dehydratase) (Dimerization cofactor of P61457 hepatocyte nuclear factor 1-alpha) (DCoH) (Dimerization cofactor of PCBD1 1.067 0.0 Infinity 0.036 HNF1) (Phenylalanine hydroxylase-stimulating protein) (Pterin carbinolamine dehydratase) (PCD) Q5R3I4 Tetratricopeptide repeat protein 38 (TPR repeat protein 38) TTC38 0.933 0.0 Infinity 0.047 Lysosomal alpha-mannosidase (Laman) (EC 3.2.1.24) (Lysosomal acid alpha-mannosidase) (Mannosidase alpha class 2B member 1) (Mannosidase alpha-B) [Cleaved into: Lysosomal alpha-mannosidase A O00754 MAN2B1 6.800 0.0 Infinity 0.049 peptide; Lysosomal alpha-mannosidase B peptide; Lysosomal alpha- mannosidase C peptide; Lysosomal alpha-mannosidase D peptide; Lysosomal alpha-mannosidase E peptide] Filaggrin-2 (FLG-2) (Intermediate filament-associated and psoriasis- Q5D862 FLG2 0.067 2.0 30.000 0.001 susceptibility protein) (Ifapsoriasin) Glycerol-3-phosphate dehydrogenase [NAD (+)], cytoplasmic (GPD-C) P21695 GPD1 5.600 0.2 28.000 0.017 (GPDH-C) (EC 1.1.1.8) Q16610 Extracellular matrix protein 1 (Secretory component p85) ECM1 0.067 1.6 24.000 0.029 Q9NZT1 Calmodulin-like protein 5 (Calmodulin-like skin protein) CALML5 0.133 2.8 21.000 0.011 Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) Q15274 (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) QPRT 4.133 0.2 20.667 0.014 (QPRTase) Interleukin-2 receptor subunit beta (IL-2 receptor subunit beta) (IL-2R subunit beta) (IL-2RB) (High affinity IL-2 receptor subunit beta) P14784 IL2RB 0.133 2.6 19.500 0.002 (Interleukin-15 receptor subunit beta) (p70-75) (p75) (CD antigen CD122) Alpha-2-macroglobulin-like protein 1 (C3 and PZP-like alpha-2- A8K2U0 A2ML1 0.333 6.0 18.000 0.016 macroglobulin domain-containing protein 9) Serine hydroxymethyltransferase, cytosolic (SHMT) (EC 2.1.2.1) P34896 SHMT1 3.333 0.2 16.667 0.019 (Glycine hydroxymethyltransferase) (Serine methylase) P20930 Filaggrin FLG 0.600 10.0 16.667 0.021 D-dopachrome decarboxylase (EC 4.1.1.84) (D-dopachrome P30046 DDT 3.133 0.2 15.667 0.004 tautomerase) (Phenylpyruvate tautomerase II) Matrilysin (EC 3.4.24.23) (Matrin) (Matrix metalloproteinase-7) (MMP- P09237 MMP7 3.067 0.2 15.333 0.039 7) (Pump-1 protease) (Uterine metalloproteinase) P31151 Protein S100-A7 (Psoriasin) (S100 calcium-binding protein A7) S100A7 0.467 7.0 15.000 0.002 Lambda-crystallin homolog (EC 1.1.1.45) (L-gulonate 3-dehydrogenase) Q9Y2S2 CRYL1 2.733 0.2 13.667 0.021 (Gul3DH) CD83 antigen (hCD83) (B-cell activation protein) (Cell surface protein Q01151 CD83 0.133 1.8 13.500 0.001 HB15) (CD antigen CD83) Q8TAB3 Protocadherin-19 PCDH19 0.067 0.8 12.000 0.022 Complement component C8 beta chain (Complement component 8 P07358 C8B 0.133 1.6 12.000 0.038 subunit beta) P18206 Vinculin (Metavinculin) (MV) VCL 0.067 0.8 12.000 0.044 Q86Y78 Ly6/PLAUR domain-containing protein 6 LYPD6 0.067 0.8 12.000 0.044 Phospholipase B-like 1 (EC 3.1.1.-) (LAMA-like protein 1) (Lamina ancestor homolog 1) (Phospholipase B domain-containing protein 1) Q6P4A8 PLBD1 0.067 0.8 12.000 0.044 [Cleaved into: Phospholipase B-like 1 chain A; Phospholipase B-like 1 chain B; Phospholipase B-like 1 chain C] N (G),N (G)-dimethylarginine dimethylaminohydrolase 1 (DDAH-1) O94760 (Dimethylarginine dimethylaminohydrolase 1) (EC 3.5.3.18) (DDAHI) DDAH1 3.933 0.4 9.833 0.026 (Dimethylargininase-1) Azurocidin (Cationic antimicrobial protein CAP37) (Heparin-binding P20160 AZU1 0.400 3.8 9.500 0.044 protein) (HBP) (hHBP) Filamin-B (FLN-B) (ABP-278) (ABP-280 homolog) (Actin-binding-like O75369 protein) (Beta-filamin) (Filamin homolog 1) (Fh1) (Filamin-3) (Thyroid FLNB 0.333 3.0 9.000 0.002 autoantigen) (Truncated actin-binding protein) (Truncated ABP) Myeloperoxidase (MPO) (EC 1.11.2.2) [Cleaved into: Myeloperoxidase; P05164 89 kDa myeloperoxidase; 84 kDa myeloperoxidase; Myeloperoxidase MPO 1.667 14.8 8.880 0.036 light chain; Myeloperoxidase heavy chain] Palmitoyl-protein thioesterase 1 (PPT-1) (EC 3.1.2.22) (Palmitoyl- P50897 PPT1 3.333 0.4 8.333 0.040 protein hydrolase 1) Lysosomal acid glucosylceramidase (Lysosomal acid GCase) (EC 3.2.1.45) (Acid beta-glucosidase) (Alglucerase) (Beta- P04062 glucocerebrosidase) (Beta-GC) (Cholesterol glucosyltransferase) GBA 1.600 0.2 8.000 0.045 (SGTase) (EC 2.4.1.-) (Cholesteryl-beta-glucosidase) (EC 3.2.1.104) (D- glucosyl-N-acylsphingosine glucohydrolase) (Imiglucerase) Tumor necrosis factor receptor superfamily member EDAR (Anhidrotic Q9UNE0 ectodysplasin receptor 1) (Downless homolog) (EDA-A1 receptor) EDAR 0.267 2.0 7.500 0.031 (Ectodermal dysplasia receptor) (Ectodysplasin-A receptor) P46940 Ras GTPase-activating-like protein IQGAP1 (p195) IQGAP1 0.333 2.2 6.600 0.001 Annexin A1 (Annexin I) (Annexin-1) (Calpactin II) (Calpactin-2) P04083 (Chromobindin-9) (Lipocortin I) (Phospholipase A2 inhibitory protein) ANXA1 1.133 7.4 6.529 0.035 (p35) Fractalkine (C-X3-C motif chemokine 1) (CX3C membrane-anchored P78423 chemokine) (Neurotactin) (Small-inducible cytokine D1) [Cleaved into: CX3CL1 0.333 2.0 6.000 0.004 Processed fractalkine] Interleukin-1 receptor accessory protein (IL-1 receptor accessory protein) Q9NPH3 IL1RAP 2.400 0.4 6.000 0.003 (IL-1RAcP) (EC 3.2.2.6) (Interleukin-1 receptor 3) (IL-1R-3) (IL-1R3) Q969H8 Myeloid-derived growth factor (MYDGF) MYDGF 3.533 0.6 5.889 0.003 Angiotensin-converting enzyme 2 (EC 3.4.17.23) (ACE-related carboxypeptidase) (Angiotensin-converting enzyme homolog) (ACEH) Q9BYF1 ACE2 3.400 0.6 5.667 0.033 (Metalloprotease MPROT15) [Cleaved into: Processed angiotensin- converting enzyme 2] Gamma-glutamylaminecyclotransferase (GGACT) (EC 4.3.2.8) (AIG2- Q9BVM4 like domain-containing protein 1) (Gamma-glutamylamine GGACT 2.267 0.4 5.667 0.040 cyclotransferase) Cytosolic non-specific dipeptidase (EC 3.4.13.18) (CNDP dipeptidase 2) Q96KP4 (Carnosine dipeptidase II) (Epididymis secretory protein Li 13) CNDP2 7.667 1.4 5.476 0.014 (Glutamate carboxypeptidase-like protein 1) (Peptidase A) C-type lectin domain family 5 member A (C-type lectin superfamily Q9NY25 CLEC5A 0.267 1.4 5.250 0.004 member 5) (Myeloid DAP12-associating lectin 1) (MDL-1) P17050 Alpha-N-acetylgalactosaminidase (EC 3.2.1.49) (Alpha-galactosidase B) NAGA 10.333 2.0 5.167 0.009 Gamma-glutamylcyclotransferase (EC 4.3.2.9) (Cytochrome c-releasing O75223 GGCT 0.467 2.4 5.143 0.004 factor 21) Neutrophil elastase (EC 3.4.21.37) (Bone marrow serine protease) P08246 (Elastase-2) (Human leukocyte elastase) (HLE) (Medullasin) (PMN ELANE 0.467 2.4 5.143 0.046 elastase) N-sulphoglucosamine sulphohydrolase (EC 3.10.1.1) (Sulfoglucosamine P51688 SGSH 15.067 3.0 5.022 0.031 sulfamidase) (Sulphamidase) Serum amyloid P-component (SAP) (9.5S alpha-1-glycoprotein) P02743 APCS 0.400 2.0 5.000 0.036 [Cleaved into: Serum amyloid P-component (1-203)] Protein/nucleic acid deglycase DJ-1 (EC 3.1.2.-) (EC 3.5.1.-) (EC Q99497 3.5.1.124) (Maillard deglycase) (Oncogene DJ1) (Parkinson disease PARK7 6.733 1.4 4.810 0.001 protein 7) (Parkinsonism-associated deglycase) (Protein DJ-1) (DJ-1) Group XV phospholipase A2 (EC 2.3.1.-) (1-O-acylceramide synthase) Q8NCC3 (ACS) (LCAT-like lysophospholipase) (LLPL) (Lysophospholipase 3) PLA2G15 5.733 1.2 4.778 0.013 (Lysosomal phospholipase A2) (LPLA2) Fumarylacetoacetase (FAA) (EC 3.7.1.2) (Beta-diketonase) P16930 FAH 2.867 0.6 4.778 0.028 (Fumarylacetoacetate hydrolase) Alcohol dehydrogenase class-3 (EC 1.1.1.1) (Alcohol dehydrogenase 5) (Alcohol dehydrogenase class chi chain) (Alcohol dehydrogenase class- P11766 III) (Glutathione-dependent formaldehyde dehydrogenase) (FALDH) ADH5 2.867 0.6 4.778 0.031 (FDH) (GSH-FDH) (EC 1.1.1.-) (S- (hydroxymethyl)glutathione dehydrogenase) (EC 1.1.1.284) 5'-3' exonuclease PLD3 (EC 3.1.16.1) (Choline phosphatase
Load more

Recommended publications
  • Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2
    Supplementary Table 3 Complete list of RNA-Sequencing analysis of gene expression changed by ≥ tenfold between xenograft and cells cultured in 10%O2 Expr Log2 Ratio Symbol Entrez Gene Name (culture/xenograft) -7.182 PGM5 phosphoglucomutase 5 -6.883 GPBAR1 G protein-coupled bile acid receptor 1 -6.683 CPVL carboxypeptidase, vitellogenic like -6.398 MTMR9LP myotubularin related protein 9-like, pseudogene -6.131 SCN7A sodium voltage-gated channel alpha subunit 7 -6.115 POPDC2 popeye domain containing 2 -6.014 LGI1 leucine rich glioma inactivated 1 -5.86 SCN1A sodium voltage-gated channel alpha subunit 1 -5.713 C6 complement C6 -5.365 ANGPTL1 angiopoietin like 1 -5.327 TNN tenascin N -5.228 DHRS2 dehydrogenase/reductase 2 leucine rich repeat and fibronectin type III domain -5.115 LRFN2 containing 2 -5.076 FOXO6 forkhead box O6 -5.035 ETNPPL ethanolamine-phosphate phospho-lyase -4.993 MYO15A myosin XVA -4.972 IGF1 insulin like growth factor 1 -4.956 DLG2 discs large MAGUK scaffold protein 2 -4.86 SCML4 sex comb on midleg like 4 (Drosophila) Src homology 2 domain containing transforming -4.816 SHD protein D -4.764 PLP1 proteolipid protein 1 -4.764 TSPAN32 tetraspanin 32 -4.713 N4BP3 NEDD4 binding protein 3 -4.705 MYOC myocilin -4.646 CLEC3B C-type lectin domain family 3 member B -4.646 C7 complement C7 -4.62 TGM2 transglutaminase 2 -4.562 COL9A1 collagen type IX alpha 1 chain -4.55 SOSTDC1 sclerostin domain containing 1 -4.55 OGN osteoglycin -4.505 DAPL1 death associated protein like 1 -4.491 C10orf105 chromosome 10 open reading frame 105 -4.491
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Supplementary Table 1. the List of Proteins with at Least 2 Unique
    Supplementary table 1. The list of proteins with at least 2 unique peptides identified in 3D cultured keratinocytes exposed to UVA (30 J/cm2) or UVB irradiation (60 mJ/cm2) and treated with treated with rutin [25 µM] or/and ascorbic acid [100 µM]. Nr Accession Description 1 A0A024QZN4 Vinculin 2 A0A024QZN9 Voltage-dependent anion channel 2 3 A0A024QZV0 HCG1811539 4 A0A024QZX3 Serpin peptidase inhibitor 5 A0A024QZZ7 Histone H2B 6 A0A024R1A3 Ubiquitin-activating enzyme E1 7 A0A024R1K7 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 8 A0A024R280 Phosphoserine aminotransferase 1 9 A0A024R2Q4 Ribosomal protein L15 10 A0A024R321 Filamin B 11 A0A024R382 CNDP dipeptidase 2 12 A0A024R3V9 HCG37498 13 A0A024R3X7 Heat shock 10kDa protein 1 (Chaperonin 10) 14 A0A024R408 Actin related protein 2/3 complex, subunit 2, 15 A0A024R4U3 Tubulin tyrosine ligase-like family 16 A0A024R592 Glucosidase 17 A0A024R5Z8 RAB11A, member RAS oncogene family 18 A0A024R652 Methylenetetrahydrofolate dehydrogenase 19 A0A024R6C9 Dihydrolipoamide S-succinyltransferase 20 A0A024R6D4 Enhancer of rudimentary homolog 21 A0A024R7F7 Transportin 2 22 A0A024R7T3 Heterogeneous nuclear ribonucleoprotein F 23 A0A024R814 Ribosomal protein L7 24 A0A024R872 Chromosome 9 open reading frame 88 25 A0A024R895 SET translocation 26 A0A024R8W0 DEAD (Asp-Glu-Ala-Asp) box polypeptide 48 27 A0A024R9E2 Poly(A) binding protein, cytoplasmic 1 28 A0A024RA28 Heterogeneous nuclear ribonucleoprotein A2/B1 29 A0A024RA52 Proteasome subunit alpha 30 A0A024RAE4 Cell division cycle 42 31
    [Show full text]
  • Usbiological Datasheet
    Cytosol Nonspecific Dipeptidase 2, Recombinant, Human (CNDP2, CPGL, Glutamate Carboxypeptidase- Like Protein 1, Peptidase A, Tissue Carnosinase) Catalog number C9090-50 Supplier United States Biological The human CNDP2 gene encodes cytosol nonspecific dipeptidase, a member of the M20 family of metalloproteases (2, 3). Also known as glutamate carboxypeptidase-like protein 1 (CPGL), tissue carnosinase or peptidase A, CNDP2 is ubiquitously expressed throughout human tissues. Unlike CNDP1, CNDP2 has broad substrate specificity for dipeptides with free amino and carboxyl groups. Source Recombinant human cytosolic nonspecific dipeptidase encoded by the CNDP2 gene (human CNDP2, residue 1-475; Accession# Q96KP4) (1,2) was expressed with a C-terminal 10X His tag in Sf21 insect cells. Molecular Mass The purified rhCNDP2 migrates as three bands in SDS-PAGE with molecular masses of approximately 54, 38 and 22 kD. The 54 kD band corresponds to the full-length protein (485 amino acids). The 38 and 22 kD bands correspond to the N- and C-terminal fragments, respectively. The N-terminal sequencing of rhCNDP2 revealed only S 299HKKDILMHR, which corresponds to the N-terminus of the 22kD fragment. Endotoxin Level < 1.0 EU per 1 μg of the protein as determined by the LAL method. Activity Measure by its ability to cleave carnosine (β-Ala-His) in a two-step assay. See Activity Assay protocol on next page for details. The specific activity, as measured using the procedure above, is > 70 pmoles/min/μg. Storage Samples are stable for up to six months at -70° C in a manual defrost freezer after the receipt. After receiving, this enzyme can be aliquoted and stored under the above temperature for six months without a significant loss of activity.
    [Show full text]
  • Electronic Supplementary Material (ESI) for Analyst. This Journal Is © the Royal Society of Chemistry 2020
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 Table S1.
    [Show full text]
  • Protein Symbol Protein Name Rank Metric Score 4F2 4F2 Cell-Surface
    Supplementary Table 2 Supplementary Table 2. Ranked list of proteins present in anti-Sema4D treated macrophage conditioned media obtained in the GSEA analysis of the proteomic data. Proteins are listed according to their rank metric score, which is the score used to position the gene in the ranked list of genes of the GSEA. Values are obtained from comparing Sema4D treated RAW conditioned media versus REST, which includes untreated, IgG treated and anti-Sema4D added RAW conditioned media. GSEA analysis was performed under standard conditions in November 2015. Protein Rank metric symbol Protein name score 4F2 4F2 cell-surface antigen heavy chain 2.5000 PLOD3 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 1.4815 ELOB Transcription elongation factor B polypeptide 2 1.4350 ARPC5 Actin-related protein 2/3 complex subunit 5 1.2603 OSTF1 teoclast-stimulating factor 1 1.2500 RL5 60S ribomal protein L5 1.2135 SYK Lysine--tRNA ligase 1.2135 RL10A 60S ribomal protein L10a 1.2135 TXNL1 Thioredoxin-like protein 1 1.1716 LIS1 Platelet-activating factor acetylhydrolase IB subunit alpha 1.1067 A4 Amyloid beta A4 protein 1.0911 H2B1M Histone H2B type 1-M 1.0514 UB2V2 Ubiquitin-conjugating enzyme E2 variant 2 1.0381 PDCD5 Programmed cell death protein 5 1.0373 UCHL3 Ubiquitin carboxyl-terminal hydrolase isozyme L3 1.0061 PLEC Plectin 1.0061 ITPA Inine triphphate pyrophphatase 0.9524 IF5A1 Eukaryotic translation initiation factor 5A-1 0.9314 ARP2 Actin-related protein 2 0.8618 HNRPL Heterogeneous nuclear ribonucleoprotein L 0.8576 DNJA3 DnaJ homolog subfamily
    [Show full text]
  • Mapping of the Active Site of Glutamate Carboxypeptidase II by Site
    Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis Petra Mlcˇochova´ 1,2*, Anna Plechanovova´ 1,2*,†, Cyril Barˇinka1,‡, Daruka Mahadevan3, Jose W. Saldanha4, Lubomı´r Rulı´sˇek1 and Jan Konvalinka1,2 1 Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic 2 Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic 3 Department of Medicine, Hematology ⁄ Oncology, Arizona Cancer Center, Tucson, AZ, USA 4 National Institute for Medical Research, Division of Mathematical Biology, London, UK Keywords Human glutamate carboxypeptidase II [GCPII (EC 3.4.17.21)] is recog- active site; metallopeptidase; mutagenesis; nized as a promising pharmacological target for the treatment and imaging NAALADase; prostate specific membrane of various pathologies, including neurological disorders and prostate can- antigen cer. Recently reported crystal structures of GCPII provide structural Correspondence insight into the organization of the substrate binding cavity and highlight J. Konvalinka, Institute of Organic Chemistry residues implicated in substrate ⁄ inhibitor binding in the S1¢ site of the and Biochemistry, Academy of Sciences of enzyme. To complement and extend the structural studies, we constructed the Czech Republic, Flemingovo n. 2, a model of GCPII in complex with its substrate, N-acetyl-l-aspartyl-l-glu- 166 10 Praha 6, Czech Republic tamate, which enabled us to predict additional amino acid residues inter- Fax: +420 220 183578 acting with the bound substrate, and used site-directed mutagenesis to Tel: +420 220 183218 assess the contribution of individual residues for substrate ⁄ inhibitor bind- E-mail: [email protected] ing and enzymatic activity of GCPII.
    [Show full text]
  • Genome-Wide Profiling of Druggable Active Tumor Defense Mechanisms to Enhance Cancer Immunotherapy
    bioRxiv preprint doi: https://doi.org/10.1101/843185; this version posted November 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy Rigel J. Kishton1,2,*,#, Shashank J. Patel1,2,†,*, Suman K. Vodnala1,2, Amy E. Decker3, Yogin Patel1,2, Madhusudhanan Sukumar1,2, Tori N. Yamamoto1,2,4, Zhiya Yu1,2, Michelle Ji1,2, Amanda N. Henning1,2, Devikala Gurusamy1,2, Douglas C. Palmer1,2, Winifred Lo1, Anna Pasetto1, Parisa Malekzadeh1, Drew C. Deniger1, Kris C. Wood3, Neville E. Sanjana5,6, Nicholas P. Restifo1,2, #, § 1Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA 2Center for Cell-Based Therapy, National Cancer Institute, Bethesda, MD 20892, USA 3Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC, USA 4Immunology Graduate Group, University of Pennsylvania, Philadelphia, PA 19104, USA 5New York Genome Center, New York, NY 10013 USA 6Department of Biology, New York University, New York, NY 10003, USA *These authors contributed equally to this work. †Present address: NextCure Inc., Beltsville, MD 20705, USA §Present address: Lyell Immunopharma, South San Francisco, CA 94080, USA #Corresponding authors. NPR: [email protected]. RJK: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/843185; this version posted November 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
    [Show full text]